BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women’s healthcare company, commented today on yesterday’s passage of H.R. 3204, the Drug Quality and Security Act.
Robert Finizio, Chief Executive Officer and Co-founder of TherapeuticsMD, said, “The Drug Quality and Security Act is intended to improve the safety of drugs manufactured by compounding pharmacies in the United States and is a vital step for protecting public health. We applaud the many legislators in both houses of Congress who came together in a strong bipartisan effort to pass this critical legislation.
Help employers find you! Check out all the jobs and post your resume.